Drug Trial Radar · NCT05267613
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 1, 2022
Primary completion
Aug 10, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- IQVIA RDS Inc.; Calyx; Laboratory Corporation of America; Medidata Solutions; Thermo Fisher Scientific, Inc; CISCRP; Quipment Inc.; Little Journey Ltd.
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Conditions
- Erosive Esophagitis
Interventions
Nexium 20mgDrug
Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Nexium 10mgDrug
Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence / absence of Erosive EsophagitisTime frame: Week 24 (end of 16-week maintenance phase)
Locations
41 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Sacramento, California
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Carmel, Indiana
Research Site
Shreveport, Louisiana
Research Site
The Bronx, New York
Research Site
Akron, Ohio
Research Site
Cleveland, Ohio
Research Site
Milwaukee, Wisconsin
Research Site
Córdoba, Argentina
Research Site
Córdoba, Argentina
Research Site
Paraná, Argentina
Research Site
Rosario, Argentina
Research Site
Clayton, Australia
Research Site
Namur, Belgium
Research Site
Athens, Greece
Research Site
Thessaloniki, Greece
Research Site
Thessaloniki, Greece
Research Site
Messina, Italy
Research Site
Naples, Italy
Research Site
Naples, Italy
Research Site
Roma, Italy
Research Site
Roma, Italy
Research Site
Vilnius, Lithuania
Research Site
Coimbra, Portugal
Research Site
Lisbon, Portugal
Research Site
Lisbon, Portugal
Research Site
Lisbon, Portugal
Research Site
Porto, Portugal
Research Site
Porto, Portugal
Research Site
Viana do Castelo, Portugal
Research Site
Badalona, Spain
Research Site
Santiago de Compostela, Spain
Research Site
Seville, Spain
Research Site
Seville, Spain
Research Site
Hà Nội, Vietnam
Research Site
Hanoi, Vietnam
Research Site
Hanoi, Vietnam
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.